Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.

Ilaria Trestini,Salvatore Paiella,Marta Sandini,Thomas Hank,Tommaso Pollini,Isabella Sperduti,Davide Melisi,A. Auriemma,Caterina Soldà,Daniela Tregnago,Alice Avancini,Giuseppe Malleo,Mirko DOnofrio,Luca Gianotti,Sara Pilotto,Emilio Bria,Roberto Salvia,Carlos Fernandez-del-Castillo,Claudio Bassi,Michele Milella

Sarcopenia and sarcopenic obesity in pancreatic ductal adenocarcinoma (PDAC) patients undergoing surgery after neoadjuvant therapy (NAT): Clinical implications.

2020

e16769Background: Nutritional status may be markedly affected by NAT for PDAC. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associate...

Keywords:

Sarcopenic obesity
Oncology
Neoadjuvant therapy
Internal medicine
Pathology
Sarcopenia
pancreatic ductal adenocarcinoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations